138 related articles for article (PubMed ID: 19004731)
1. [Targeted treatments: which imaging?].
Lassau N; Chebil M; Benatsou B; Chami L; Roche A
Bull Cancer; 2008 Oct; 95(10):989-93. PubMed ID: 19004731
[TBL] [Abstract][Full Text] [Related]
2. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives.
Marcus CD; Ladam-Marcus V; Cucu C; Bouché O; Lucas L; Hoeffel C
Crit Rev Oncol Hematol; 2009 Dec; 72(3):217-38. PubMed ID: 18760935
[TBL] [Abstract][Full Text] [Related]
3. Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment.
Cuenod CA; Fournier L; Balvay D; Guinebretière JM
Abdom Imaging; 2006; 31(2):188-93. PubMed ID: 16447089
[TBL] [Abstract][Full Text] [Related]
4. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
Choyke PL; Dwyer AJ; Knopp MV
J Magn Reson Imaging; 2003 May; 17(5):509-20. PubMed ID: 12720260
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
Rosen MA; Schnall MD
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
[TBL] [Abstract][Full Text] [Related]
6. Tracer kinetics analysis of dynamic contrast-enhanced CT and MR data in patients with squamous cell carcinoma of the upper aerodigestive tract: comparison of the results.
Bisdas S; Baghi M; Wagenblast J; Bisdas T; Thng CH; Mack MG; Koh TS; Ernemann U
Clin Physiol Funct Imaging; 2009 Sep; 29(5):339-46. PubMed ID: 19473200
[TBL] [Abstract][Full Text] [Related]
7. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.
Desar IM; van Herpen CM; van Laarhoven HW; Barentsz JO; Oyen WJ; van der Graaf WT
Cancer Treat Rev; 2009 Jun; 35(4):309-21. PubMed ID: 19136215
[TBL] [Abstract][Full Text] [Related]
8. Imaging of tumor physiology: impacts on clinical radiation oncology.
Astner ST; Shi K; Vaupel P; Molls M
Exp Oncol; 2010 Sep; 32(3):149-52. PubMed ID: 21403609
[TBL] [Abstract][Full Text] [Related]
9. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.
Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563
[TBL] [Abstract][Full Text] [Related]
10. Perfusion measurement using DCE-MRI: implications for hyperthermia.
Lüdemann L; Wust P; Gellermann J
Int J Hyperthermia; 2008 Feb; 24(1):91-6. PubMed ID: 18214772
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
Hylton N
J Clin Oncol; 2006 Jul; 24(20):3293-8. PubMed ID: 16829653
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the tumor microenvironment in cervix cancer using dynamic contrast enhanced CT, interstitial fluid pressure and oxygen measurements.
Haider MA; Milosevic M; Fyles A; Sitartchouk I; Yeung I; Henderson E; Lockwood G; Lee TY; Roberts TP
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1100-7. PubMed ID: 15990015
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
14. [The imaging aspects of metastases from urological malignancies].
Correas JM; Méjean A; Hélénon O
Prog Urol; 2008 Nov; 18 Suppl 7():S196-201. PubMed ID: 19070791
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate.
Bonekamp D; Macura KJ
Top Magn Reson Imaging; 2008 Dec; 19(6):273-84. PubMed ID: 19512849
[TBL] [Abstract][Full Text] [Related]
16. Perfusion magnetic resonance imaging in psychiatry.
Théberge J
Top Magn Reson Imaging; 2008 Apr; 19(2):111-30. PubMed ID: 19363433
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of tumour response to treatment with targeted therapies: standard or targeted criteria?].
Menu Y
Bull Cancer; 2007; 94(7 Suppl):F231-9. PubMed ID: 17965002
[TBL] [Abstract][Full Text] [Related]
18. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
[TBL] [Abstract][Full Text] [Related]
19. How to assess anti-tumour efficacy by imaging techniques.
Gwyther SJ; Schwartz LH
Eur J Cancer; 2008 Jan; 44(1):39-45. PubMed ID: 18060765
[TBL] [Abstract][Full Text] [Related]
20. Imaging the effects of anti-angiogenic treatments.
Vāvere AL; Lewis JS
Q J Nucl Med; 2003 Sep; 47(3):163-70. PubMed ID: 12897708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
